gRNA全球市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球gRNA市場預計將從2025年的12.9億美元成長至2034年的59.8億美元，2026年至2034年的複合年成長率（CAGR）將達到18.58%。隨著基因編輯技術在生物醫學研究、藥物研發和精準醫療領域的重要性日益凸顯，該市場正迅速擴張。引導RNA（gRNA）在基於CRISPR的基因編輯中發揮著至關重要的作用，它能夠以高特異性和精確度誘導基因組修飾。基因研究投入的增加、對先進療法需求的成長以及在農業和生物技術領域應用的不斷拓展，都是推動市場顯著成長的主要因素。基因組工程的持續創新也進一步促進了該產業的發展。

生技公司和研究機構正大力投資開發高品質的合成gRNA產品，以提高基因編輯的效率和可靠性。 CRISPR平台、核酸合成和遞送系統的技術進步正在拓展多個科學領域的研究能力。製藥公司與學術機構之間日益密切的合作正在加速基因治療和功能基因組學領域的創新。生命科學研究經費的增加也促進了市場擴張。

隨著精準醫療和基因編輯技術的不斷發展，未來前景一片光明。人工智慧驅動的基因組設計、改進的遞送技術以及新一代CRISPR系統將為治療帶來新的機會。個人化醫療、再生醫學和農業生物技術的拓展將進一步增強市場需求。透過持續的研發投入，gRNA市場將成為未來基因治療的關鍵組成部分。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球gRNA市場：依產品類型分類

• 市場分析、洞察與預測
• 合成gRNA
• 體外轉錄（IVT）gRNA
• 質體編碼的gRNA構建體
• RNP複合體（gRNA+Cas）
• 多重gRNA文庫

第5章：全球gRNA市場：按應用分類

• 市場分析、洞察與預測
• 基因組編輯
• 功能基因組篩檢
• 診斷
• 細胞和基因治療
• 農業生物技術

第6章 全球gRNA市場：依最終用戶分類

• 市場分析、洞察與預測
• 學術研究機構
• 生物技術和製藥公司
• 受託研究機構（CRO）
• 醫院/診斷檢查室
• 農業相關企業

第7章 全球gRNA市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Thermo Fisher Scientific
  • Integrated DNA Technologies（Danaher）
  • Merck KGaA
  • Synthego Corporation
  • Agilent Technologies
  • Twist Bioscience
  • Eurofins Genomics
  • GenScript Biotech
  • Horizon Discovery（Revvity）
  • CRISPR Therapeutics
  • Editas Medicine
  • Intellia Therapeutics
  • Beam Therapeutics
  • OriGene Technologies
  • Applied Biological Materials（abm）
  • Bioneer Corporation
  • Sangamo Therapeutics
  • Takara Bio Inc
  • Lonza Group

The global gRNA market size is expected to reach USD 5.98 Billion in 2034 from USD 1.29 Billion in 2025, growing at a CAGR of 18.58 during 2026-2034.This market is witnessing rapid expansion as gene editing technologies become increasingly important in biomedical research, drug discovery, and precision medicine. Guide RNA (gRNA) plays a critical role in CRISPR-based gene editing by directing genome modification with high specificity and accuracy. Rising investments in genetic research, increasing demand for advanced therapeutics, and expanding applications in agriculture and biotechnology are driving significant market growth. Continuous innovation in genome engineering is further supporting industry development.

Biotechnology companies and research institutions are investing heavily in the development of high-quality synthetic gRNA products to improve gene editing efficiency and reliability. Technological advancements in CRISPR platforms, nucleic acid synthesis, and delivery systems are expanding research capabilities across multiple scientific disciplines. Growing collaboration between pharmaceutical companies and academic organizations is accelerating innovation in gene therapy and functional genomics. Increased funding for life science research is also contributing to market expansion.

The future outlook remains highly encouraging as precision medicine and gene editing technologies continue evolving. Artificial intelligence-assisted genome design, improved delivery technologies, and next-generation CRISPR systems will create new opportunities for therapeutic development. Expansion of personalized medicine, regenerative therapies, and agricultural biotechnology will further strengthen demand. Continuous research and technological innovation will position the gRNA market as a vital component of future genetic medicine.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product Type

• Synthetic gRNA
• In Vitro Transcribed (IVT) gRNA
• Plasmid-Encoded gRNA Constructs
• RNP Complexes (gRNA + Cas)
• Multiplex gRNA Libraries

By Application

• Genome Editing
• Functional Genomics Screens
• Diagnostics
• Cell & Gene Therapy
• Agricultural Biotechnology

By End User

• Academic & Research Institutes
• Biotechnology & Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Hospitals & Diagnostic Laboratories
• Agro-Industrial Firms

COMPANIES PROFILED

• Thermo Fisher Scientific, Integrated DNA Technologies (Danaher), Merck KGaA, Synthego Corporation, Agilent Technologies, Twist Bioscience, Eurofins Genomics, GenScript Biotech, Horizon Discovery (Revvity), CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Beam Therapeutics, OriGene Technologies, Applied Biological Materials (abm), Bioneer Corporation, Sangamo Therapeutics, Takara Bio Inc., Lonza Group

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GRNA MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Synthetic gRNA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. In Vitro Transcribed (IVT) gRNA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Plasmid-Encoded gRNA Constructs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. RNP Complexes (gRNA + Cas) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Multiplex gRNA Libraries Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GRNA MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Genome Editing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Functional Genomics Screens Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Cell & Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Agricultural Biotechnology Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GRNA MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Biotechnology & Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Contract Research Organizations (CROs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Hospitals & Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Agro-Industrial Firms Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GRNA MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product Type
  • 7.2.2 By Application
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product Type
  • 7.3.2 By Application
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product Type
  • 7.4.2 By Application
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product Type
  • 7.5.2 By Application
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product Type
  • 7.6.2 By Application
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GRNA INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Thermo Fisher Scientific
  • 9.2.2 Integrated DNA Technologies (Danaher)
  • 9.2.3 Merck KGaA
  • 9.2.4 Synthego Corporation
  • 9.2.5 Agilent Technologies
  • 9.2.6 Twist Bioscience
  • 9.2.7 Eurofins Genomics
  • 9.2.8 GenScript Biotech
  • 9.2.9 Horizon Discovery (Revvity)
  • 9.2.10 CRISPR Therapeutics
  • 9.2.11 Editas Medicine
  • 9.2.12 Intellia Therapeutics
  • 9.2.13 Beam Therapeutics
  • 9.2.14 OriGene Technologies
  • 9.2.15 Applied Biological Materials (abm)
  • 9.2.16 Bioneer Corporation
  • 9.2.17 Sangamo Therapeutics
  • 9.2.18 Takara Bio Inc
  • 9.2.19 Lonza Group